

June 19, 2023

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	---

Dear Sirs,

**Sub: Press Release - Laurus Labs signs Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets**

The Company is pleased to announce that it has signed a Memorandum of Agreement (MOA) with IIT Kanpur (IITK) to bring novel gene therapy assets to market. As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development. Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets. Additionally, Laurus labs will establish a GMP facility at the Techno Park facility of IITK.

A press release to this extent is also enclosed for your information and records.

Thanking you,

Yours sincerely,  
For **Laurus Labs Limited**

**G. Venkateswar Reddy**  
**Company Secretary &**  
**Compliance Officer**

Encl: As above

## Laurus Labs signs Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets

**Hyderabad, June 19, 2023: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028)**

Laurus labs has signed an MOA with IIT Kanpur (IITK) to bring novel gene therapy assets to market. As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development. Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets. Additionally, Laurus labs will establish a GMP facility at the Techno Park facility of IITK.

Department of Biological Sciences and Bioengineering (BSBE) at IIT Kanpur has been working on gene therapy for the last few years and have developed few gene therapy assets along with technology for novel Adeno Associated Virus (AAV) vectors. They have filed IPs around these products and few additional patent applications will be filed in due course.

This partnership allows Laurus Labs to strengthen its presence in the promising Cell and Gene Therapy (CGT) space and allows it to become a leader in this space. These therapies are not available in India and emerging markets and this collaboration will help us in bringing these novel therapies to Indian patients at an affordable pricing. Additionally, this allows Laurus labs to offer CDMO services to cell and gene therapy companies.

**Commenting on this development, CEO of Laurus Labs Dr. Satyanarayana Chava said,** “We are very excited to partner with IIT Kanpur to bring novel gene therapy products to patients in India and other markets at an affordable pricing. This collaboration exhibits our commitment towards Cell and Gene therapy (CGT) space. This partnership also provides a unique model for industry –academia collaboration and how can we leverage strengths from both the sections for the benefit of patients. IITK has a proven record of being a flag bearer for advancing research in India and this collaboration takes it to the next level”.

**Commenting of the development, Prof. Abhay Karandikar, Director of IIT Kanpur said,** “This is a big moment for us at IIT Kanpur when we are partnering with a leading pharma company Laurus Labs for developing novel drugs based on path-breaking research in gene therapy at IIT Kanpur. With setting up of the Gangwal School of Medical Sciences and Technology, we are committed to transformative research in affordable healthcare including novel drug discovery, medical diagnostics and therapeutics, medical devices and implants. I am confident that in the years to come, this partnership with Laurus Labs will enable affordable treatment to some of the difficult to treat disorders. This also further strengthens the achievability of an industry-academia collaboration towards Atmanirbhar Bharat.”

## **About Laurus Labs**

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions of people around the world. Laurus has a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. Laurus also offers integrated Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus is passionate about continuous technological advances for Smart and Green chemistry technologies to drive efficiencies and sustainable manufacturing backed by proven regulatory and quality foundation. Laurus employs 6500+ people, including around 1250+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings. **Corporate Identification No: L24239AP2005PLC047518.**

For more information visit [www.lauruslabs.com](http://www.lauruslabs.com)

## **About IIT Kanpur:**

Indian Institute of Technology (IIT) Kanpur was established on 2nd November 1959 by an Act of Parliament. The institute has a sprawling campus spread over 1055 acres with large pool of academic and research resources spanning across 19 departments, 22 centres, and 3 Interdisciplinary programs in engineering, science, design, humanities, and management disciplines with 540 full-time faculty members and approximately 9000 students. In addition to formal undergraduate and postgraduate courses, the institute has been active in research and development in areas of value to both industry and government.

For more information, visit [www.iitk.ac.in](http://www.iitk.ac.in)

## **Contact particulars:**

---

### **Media Relations**

**Pavan Kumar N**

**Tel:** +91 40 3980 4380

**Email:**[mediarelations@lauruslabs.com](mailto:mediarelations@lauruslabs.com)

### **Investor Relations**

**Vivek Kumar**

**Tel:** +91 40 3980 4366

**Email:**[investorrelations@lauruslabs.com](mailto:investorrelations@lauruslabs.com)

---

**DISCLAIMER:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

